For research use only. Not for therapeutic Use.
SCH 527123（Cat No.:I003641）, also known as tolvaptan, is a selective vasopressin V2 receptor antagonist developed for the treatment of conditions related to fluid retention and hyponatremia. By blocking the V2 receptors in the kidneys, it inhibits the action of vasopressin, a hormone responsible for water reabsorption. This leads to increased urine output and improved fluid balance. Tolvaptan has been primarily investigated for treating conditions such as heart failure, cirrhosis, and autosomal dominant polycystic kidney disease (ADPKD), where water retention is a significant issue. Clinical studies have demonstrated its effectiveness in managing these disorders and improving patient outcomes.
| Catalog Number | I003641 |
| CAS Number | 473727-83-2 |
| Synonyms | 2-hydroxy-N,N-dimethyl-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]benzamide |
| Molecular Formula | C21H23N3O5 |
| Purity | ≥95% |
| Target | Immunology/Inflammation |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IC50 | 42 nM (CXCR1); 3 nM (CXCR2) |
| IUPAC Name | 2-hydroxy-N,N-dimethyl-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]benzamide |
| InChI | InChI=1S/C21H23N3O5/c1-5-13(15-10-9-11(2)29-15)22-16-17(20(27)19(16)26)23-14-8-6-7-12(18(14)25)21(28)24(3)4/h6-10,13,22-23,25H,5H2,1-4H3/t13-/m1/s1 |
| InChIKey | RXIUEIPPLAFSDF-CYBMUJFWSA-N |
| SMILES | CC[C@H](C1=CC=C(O1)C)NC2=C(C(=O)C2=O)NC3=CC=CC(=C3O)C(=O)N(C)C |
| Reference | <p style=/line-height:25px/> |
